<DOC>
	<DOCNO>NCT00349752</DOCNO>
	<brief_summary>The current study design measure corticosteroid-sparing effect certolizumab pegol use defined schedule corticosteroid taper subject moderate severe Crohn 's disease . Subjects remission ( CDAI &lt; =150 ) receive corticosteroid dose high 30 mg/day prednisone equivalent week prior randomization .</brief_summary>
	<brief_title>Corticosteroid Sparing Effect Certolizumab Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Men woman Age 18 year old moderate severe Crohn 's disease ( Crohn 's Disease Activity Index ( CDAI ) score ≥ 220 ≤450 ) Active drain fistula present screen Lactating and/or pregnant female subject A history health condition could potentially interfere disease and/or treatment A history adverse reaction polyethylene glycol ( PEG ) protein medicinal product Any condition Investigator 's judgment would make patient unsuitable inclusion study History drug alcohol abuse prior year Receipt experimental therapy within outside clinical trial 3 month prior Visit 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>